FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara® (Ustekinumab)

Contributed by: Business Wire

Logo

Tags

Health

FDA

Other Health

Research

Science

Pharmaceutical

Biotechnology

Dong-A ST

More Like This

CHMP Recommends the Approval of Dong-A ST’s IMULDOSA, a Biosimilar to Stelara®

Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA

Accord Healthcare receives positive CHMP opinion for IMULDOSA®, a ustekinumab biosimilar to Stelara®

PR Newswire associated0

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

European Commission approves Celltrion’s SteQeyma® (CT-P43), a biosimilar to Stelara® (ustekinumab), for the treatment of multiple chronic inflammatory diseases

Stapokibart Was Granted Marketing Approval From National Medical Products Administration For The Treatment Of Moderate-to-severe Atopic Dermatitis in Adults

FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union